Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML).

ABSTRACT: Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment modality for patients with acute myeloid leukemia (AML). Here, we investigated the predictive value of spleen volume on outcome parameters and engraftment kinetics after HSCT in a large cohort of AML patients. A total of 402 patients who received their first HSCT between January 2012 and March 2019 were included in this retrospective study. Spleen volume was correlated to clinical outcome and engraftment kinetics. Median follow-up was 33.7 months (95% confidence interval [CI], 28.9-37.4 months). Patients were subdivided based on median spleen volume of 238.0 cm³ (range 55.7-2693.5 cm³) into a small spleen volume (SSV) and a large spleen volume (LSV) group. LSV was associated with infer

SUBMITTER: Pohlmann A 

PROVIDER: S-EPMC10444671 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature